Phase Ia multi-center, blinded, placebo-controlled, single-ascending dose study of VRS-859 in patients with type 2 diabetes mellitus

Trial Profile

Phase Ia multi-center, blinded, placebo-controlled, single-ascending dose study of VRS-859 in patients with type 2 diabetes mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Jan 2016 In Dec 2015, company announced positive results from this trial, as per Flamel media release.
    • 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
    • 05 Oct 2012 EudraCT2010-019182-29 added as identifier, as reported in the abstract presented at EASD.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top